求購國內(nèi)生產(chǎn)的左氧氟沙星注射液質(zhì)量信息及說明書   [更多]

YBH，2018版   [更多]

2,6-二甲基苯胺作為基因毒性雜質(zhì)控制，它的每日最大攝入量是多少？（1.5μg/天做不到）目前找到一個(gè)雷諾嗪緩釋片在澳洲申報(bào)的資料中提到2,6-二甲基苯胺的每日最大攝入量范圍是20.4μg/天~110μg/天，有沒有哪位大神知道這兩個(gè)值的來源及推導(dǎo)過程，求助。原文如下：The sponsor also commissioned two nonclinical risk assessments on DMA relative to  potential exposure from ranolazine under the conditions of use. Both assessors referred to  methodologies advocated in the ICH guideline.21 The updated guideline permits the use of  compound-specific assessments (compared with. TTC-based acceptable intake of  1.5 μg/day) when sufficient carcinogenicity data exists, such that a compound-specific  acceptable intake can be extrapolated from measures of carcinogenic potency. Information  on the carcinogenicity of DMA is available from a 2 year dietary study in rats (NTP, 1990)  and is the only source of data on carcinogenic potency. The first nonclinical assessor referred to a follow-up report to the NTP report where  carcinogenic potential (TD50) was set at 20.4 mg/kg. By linear extrapolation the  acceptable lifetime daily intake was calculated as 0.41 μg/kg/day (24.5 μg/day for 60 kg  adult or 20.4 μg/day for 50 kg adult). The amount of DMA detected in 750 mg ranolazine  tablets after 24 months storage (1.6 μg/tablet or 3.2 μg/day based on average batch values  outlined above in Table 7) were at least 6.4 fold lower than the extrapolated acceptable  lifetime daily intake of 20.4 μg/day (for 50 kg adult at the MRHD). The assessor indicated  that this was an acceptable safety factor but recommended that the shelf life of Ranexa be  no more than 24 months to ensure ranolazine degradation was minimal. The second nonclinical assessor evaluated risk assessments conducted by other regulatory  bodies where acceptable daily levels of DMA ranged between 20.4 μg/day to 110 μg/day  (for 50 kg adult). The most conservative approach gave acceptable daily levels of  29 μg/day (20.4 μg/day for 50 kg adult) and was the same as that   [更多]

一類液體敷料升二類，如果有擅長這方面的。歡迎聯(lián)系.   [更多]

最新版，2017   [更多]

最新版   [更多]

包括但不限于立項(xiàng)研究方案思路、藥學(xué)研究過程（研究方案、處方分析、各物為分析、研究設(shè)計(jì)、正交設(shè)計(jì)、研究記錄）、質(zhì)量分析研究等（最好包括進(jìn)度管理、項(xiàng)目管理、預(yù)算等）藥學(xué)研究全套文件，而不單單是交給國家藥品審評(píng)中心的格式，所提供文件最好是word格式。可多人中標(biāo)，價(jià)格另談，萬元以上。   [更多]

普拉洛芬滴眼液分別如下，1）執(zhí)行標(biāo)準(zhǔn)號(hào)：YBH042520132）執(zhí)行標(biāo)準(zhǔn)號(hào)：YBH01132013   [更多]

包含CTD文件中的工藝驗(yàn)證部分，工藝驗(yàn)證方案、工藝驗(yàn)證報(bào)告，要求主要驗(yàn)證參數(shù)、驗(yàn)證結(jié)果要有，可以刪去產(chǎn)品相關(guān)信息，關(guān)鍵參數(shù)。   [更多]

求購吸入用乙酰半胱氨酸溶液進(jìn)口質(zhì)量信息，最新版   [更多]